Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Castle Biosciences Inc
(NQ:
CSTL
)
24.70
+0.19 (+0.78%)
Streaming Delayed Price
Updated: 11:40 AM EDT, May 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
67,804
Open
24.73
Bid (Size)
24.69 (2)
Ask (Size)
24.76 (1)
Prev. Close
24.51
Today's Range
24.60 - 24.95
52wk Range
12.07 - 25.91
Shares Outstanding
25,167,365
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
May 29, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
May 15, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Performance
YTD
+12.48%
+12.48%
1 Month
+24.37%
+24.37%
3 Month
+3.50%
+3.50%
6 Month
+24.25%
+24.25%
1 Year
+84.33%
+84.33%
More News
Read More
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
May 14, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Recap: Castle Biosciences Q4 Earnings
February 28, 2024
Via
Benzinga
Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”
May 10, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
May 08, 2024
From
Castle Biosciences Inc.
Via
Business Wire
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
May 03, 2024
From
Castle Biosciences Inc.
Via
Business Wire
CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
Via
InvestorPlace
Castle Biosciences Reports First Quarter 2024 Results
May 02, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
April 30, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
April 11, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
April 10, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
April 10, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
April 04, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Announces Updates to its Board of Directors
March 27, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
March 25, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
March 22, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
March 19, 2024
From
Castle Biosciences Inc.
Via
Business Wire
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
March 15, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
March 12, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
March 08, 2024
From
Castle Biosciences Inc.
Via
Business Wire
In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
March 07, 2024
From
Castle Biosciences Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
February 29, 2024
Via
Benzinga
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 29, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.